MHRA reviews dopamine agonist warnings over impulsive side effects
Updated
Updated · BBC.com · May 1
MHRA reviews dopamine agonist warnings over impulsive side effects
6 articles · Updated · BBC.com · May 1
The move follows BBC reports including author Sally Gardiner, who says Restless Legs Syndrome treatment left her more than £500,000 in debt over 20 years.
Hundreds of patients and families described compulsive shopping, sexual behaviour, debts, broken relationships, criminality and suicide, while some RLS patients said the drugs also worsened symptoms over time.
NICE requires monitoring for Parkinson's patients, but not RLS patients, who are mostly women; the MHRA says no medicine is risk-free and advises concerned patients to consult doctors.
Could a common prescription drug be the secret cause of thousands of life-ruining addictions?
Why were women denied warnings about a drug's devastating side effects when the risks were already known?
MHRA Upgrades Dopamine Agonist ICD Risk from "Uncommon" to "Common" After BBC Investigation Reveals 14-17% Patient Impact
Overview
In early 2026, a BBC investigation revealed that UK patient leaflets severely underestimated the risks of impulse control disorders (ICDs) linked to dopamine agonist drugs, labeling them as 'uncommon' despite evidence showing they affect up to 17% of users. This prompted the MHRA to admit a disconnect between actual risks and warnings, leading to a major label overhaul upgrading ICD risks to 'common' and mandating mandatory patient counseling and regular monitoring. Patients shared devastating stories of financial ruin and relationship breakdowns caused by these side effects, while pharmaceutical companies and doctors were criticized for failing to adequately warn patients. Despite reforms, ongoing gaps in clinical practice and public trust highlight the need for continued vigilance and transparency.